MRNA-1083 is under clinical development by Moderna and currently in Phase II for Influenza A Virus, H3N2 Subtype Infections. According to GlobalData, Phase II drugs for Influenza A Virus, H3N2 Subtype Infections have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MRNA-1083’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MRNA-1083 overview
mRNA-1083 is under development for the prevention of influenza virus infection caused by influenza A/H1N1, A/H3N2, and influenza B/Yamagata and B/Victoria strains and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in 18 to 79 years of age group. It is a combination vaccine of mRNA-1283, which encodes Receptor Binding Doman (RBD) and N-Terminal Domain (NTD) of the spike protein and mRNA-1010, which encodes hemagglutinin (HA) glycoproteins of influenza A/H1N1, A/H3N2, and influenza B/Yamagata and B/Victoria-lineages. It is administered through intramuscular route in the form of sterile liquid for injection.
Moderna overview
Moderna is a biotechnology company that focuses on the development of messenger RNA therapeutics and vaccines. The company develops and discovers drugs that produce proteins or antibodies inside patient cells. Its pipeline includes various drug modalities such as prophylactic vaccines, therapeutic vaccines, intratumoral immuno-oncology, localized therapeutics, and liver intracellular. Moderna through its mRNA therapeutics platform develops and produces human proteins, antibodies, and novel proteins, which help in preventing, treating, and curing diseases. It also develops therapeutics in the areas of infectious disease, rare liver disease, immuno-oncology, and cardiovascular disease. Moderna Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of MRNA-1083’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
